NCT02570191View on ClinicalTrials.gov

A Study of PEGASYS (Peginterferon Alfa-2a [40KD]) in Patients With Hepatitis B e Antigen (HBeAg)-Negative Chronic Hepatitis B Virus (HBV)

PHASE4CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

November 30, 2004

Primary Completion Date

February 28, 2007

Study Completion Date

February 28, 2007

Conditions
Hepatitis B, Chronic
Interventions
DRUG

Peginterferon alfa-2a

180 uG in 0.5 mL solution administered once weekly for 48 weeks

Trial Locations (8)

1233

Sofia

1431

Sofia

1527

Sofia

1606

Sofia

1612

Sofia

4002

Plovdiv

5800

Pleven

6000

Stara Zagora

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT02570191 - A Study of PEGASYS (Peginterferon Alfa-2a [40KD]) in Patients With Hepatitis B e Antigen (HBeAg)-Negative Chronic Hepatitis B Virus (HBV) | Biotech Hunter | Biotech Hunter